Cork, Ireland – Apr 08, 2010 – Radisens Diagnostics has been awarded funding to develop portable diagnostic instruments for the early screening of various cancers at point-of-care. This funding was awarded as part of a large scale European nano research consortium led by Trinity College Dublin (TCD).

TCD’s Institute of Molecular Medicine (IMM) and School of Medicine, in partnership with it’s nanoscience research institute, CRANN, will lead this pan-European team that has attracted funding worth approximately €12m, to develop new nanomedical technology which will enable the early and rapid diagnosis of cancer. Radisens will concentrate on developing highly sensitive portable diagnostic platforms, targeting early cancer screening in point-of-care environments such as GP clinics, community centres and outpatient departments.

Professor Dermot Kelleher, Head of TCD School of Medicine and IMM Director said:  “This is a huge vote of confidence and recognises Irish leadership in the cutting edge field of nanomedicine.  This research programme will address some of the most important questions in human medicine relating to diagnosis and treatment of cancer, using 21st century experience and know-how in nanotechnology, and we are looking forward to the time when patients will benefit from these innovative technologies.”

“This is a huge endorsement in the innovative platform technology we are developing at Radisens” said Jerry O’Brien, CEO of Radisens. “Developing a portable handheld instrument to screen for various cancers using a pin-prick of blood will add significantly to early cancer diagnosis and increased survival rates”.

About Radisens Diagnostics
Radisens Diagnostics develops disruptive point-of-care diagnostic platforms and multiplexed test panels, which diagnose and monitor patients for multiple chronic and acute care conditions. This is the only point-of-care platform to integrate immunoassay, biochemistry and cellular haematology onto a single test panel. Using a finger-prick of blood, the analyser returns laboratory-grade results in the doctor’s office within minutes. Radisens Diagnostics is a convergence of medical diagnostics and consumer electronics using disruptive patent pending technology to deliver on the significant market and clinical need for decentralising diagnostics into point of care settings such as doctor’s offices, outpatient and emergency room departments, intensive care units and hospital bedsides.

About the Cancer Research Programme
TCD School of Medicine and CRANN Principal Investigator, Professor Yuri Volkov, will lead a European team of researchers to create advanced medical diagnostic devices, enabled by nanotechnology, which will allow the early and rapid diagnosis of cancer.   Importantly the new technology when developed will also enable the early detection of specific cancer types, leading to improved patient care. The programme will be led by a team of clinical medical researchers from St James Hospital Campus, in collaboration with the nanoscience Institute CRANN at TCD.

Commercial Contact:
E: info @ radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909